Boehringer's anti-clotting drug Pradaxa gains EU approval

08/4/2011 | Reuters

The European Commission approved Boehringer Ingelheim's Pradaxa for preventing stroke in people with atrial fibrillation. The approval underscores Boehringer's lead over other drugmakers in replacing anticoagulant warfarin.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Director of Governmental Programs
Bluegrass Family Health
Lexington, KY